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Genome‐wide mapping of plasma protein QTLs
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Identifying genetic variants associated with circulating protein concentrations (protein
quantitative trait loci; pQTLs) and integrating them with variants from genome-wide asso-
ciation studies (GWAS) may illuminate the proteome’s causal role in disease and bridge a
knowledge gap regarding SNP-disease associations. We provide the results of GWAS of 71
high-value cardiovascular disease proteins in 6861 Framingham Heart Study participants and
independent external replication. We report the mapping of over 16,000 pQTL variants and
their functional relevance. We provide an integrated plasma protein-QTL database. Thirteen
proteins harbor pQTL variants that match coronary disease-risk variants from GWAS or test
causal for coronary disease by Mendelian randomization. Eight of these proteins predict new-
onset cardiovascular disease events in Framingham participants. We demonstrate that
identifying pQTLs, integrating them with GWAS results, employing Mendelian randomization,
and prospectively testing protein-trait associations holds potential for elucidating causal
genes, proteins, and pathways for cardiovascular disease and may identify targets for its
prevention and treatment.
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Considerable progress has been made in identifying thegenetic underpinnings of coronary heart disease (CHD)1–3, which remains the leading cause of death worldwide4.
Proteins, which are the functional products encoded by the
genome, serve critical roles in biological processes involved in
health and disease, and constitute effective drug targets. While
numerous proteins have been reported to be associated with
CHD, it is often difﬁcult to establish whether they are causally
related to CHD risk or represent downstream markers of CHD-
related processes. Therefore, identifying genetic variants asso-
ciated with circulating protein levels (protein quantitative trait
loci; pQTLs), characterizing pQTL variants that also are asso-
ciated with CHD in genome-wide association studies (GWAS),
and inferring causality can provide insights into the roles of
genetic variants, genes, and proteins in the pathogenesis of CHD.
To date, most pQTL studies have been limited by small sample
sizes, lack of integration of pQTL variants with disease-associated
SNPs from GWAS, no causal testing, and cross-sectional designs
that prevented longitudinal analyses of informative protein-trait
associations5–14.
To address this knowledge gap, we conducted a multistage
study (Fig. 1), consisting ﬁrst of GWAS of high-value plasma
proteins associated with cardiovascular disease (CVD) that were
measured in Framingham Heart Study (FHS) participants. These
GWAS results were then externally replicated in participants
from the INTERVAL15 and Cooperative Health Research in the
Region of Augsburg (KORA) studies11. Third, we integrated
pQTL variants with genetic variants from the CARDIo-
GRAMplusC4D consortium databases1–3 and employed Mende-
lian randomization (MR)16 to reveal proteins with potentially
causal effects on CHD. Last, we tested proteins for associations
with new-onset CVD events in FHS participants with long-term
follow-up. We demonstrate that our strategy of protein GWAS
followed by causal testing and prospective association of proteins
with CVD outcomes can identify putatively causal genes, pro-
teins, and pathways for CVD and may highlight targets for its
prevention and treatment.
Results
Discovery set. Seventy-one proteins, selected a priori based on
prior evidence of association with CVD, were measured in 7333
FHS participants (Supplementary Data 1). The sample size
available for GWAS of the 71 proteins was up to 6861 partici-
pants (mean age 50 years, 53% women); clinical characteristics of
the discovery sample are summarized in Supplementary Data 2.
Protein assays 71 proteins measured in 7333 FHS participants
75% of cis-loci and 60% of
trans-loci replicated.
Mendelian
randomization
pQTL variants
coinciding with
CHD-related SNPs
Colocalization of pQTL
variants with eQTLs
Functional, regulatory,
and clinical annotation 
of all pQTL variants
Association with
CHD and CVD
outcomes
GWAS of 71 proteins yielded 16,602 pQTL variants
(11,806 cis; 4796 trans) representing 103 loci (40 cis,
63 trans) for 57 proteins. Of these, 36 cis-loci and 60
trans-loci (associated with 51 proteins) were
previously unreported.
Protein GWAS
Independent external replication
210 pQTL variants (9
proteins) coincided with
CHD-related SNPs
from GWAS.
Longitudinal association of 13
proteins with CHD/CVD events
identified eight at P<0.0038.
Integrative genomics analysis
Six proteins were
causal for CHD
at P<0.05.
26 of the 40 proteins with
cis-pQTLs had pQTL
variants that overlapped with
eQTLs. 16 of these 26
proteins had pQTL variants
that colocalized with eQTLs.
pQTL variants are enriched
for intergenic and intronic
regions, and linked to known
CHD risk pathways.
Fig. 1 Flowchart of Study Design. (1) Selection and measurement of 71 high-value plasma proteins for atherosclerotic CVD via multiplex immunoassays in
7333 FHS participants, (2) GWAS of the 71 proteins in 6861 FHS participants to identify genome-wide signiﬁcant pQTL variants, (3) independent external
replication of sentinel pQTLs in INTERVAL, KORA, and previous GWAS, (4) colocalization and functional enrichment analyses of the identiﬁed pQTL
variants, (5) integrated analysis of pQTL variants that coincide with CHD SNPs from GWAS, (6) identiﬁcation of causal proteins for CHD using Mendelian
randomization, (7) association analyses of proteins from steps 5 and 6 with risk for new-onset CHD/CVD events in 3520 FHS participants 50 years of age
or older with available long-term follow-up. CHD coronary heart disease, CVD cardiovascular disease, FHS Framingham Heart Study, GWAS genome-wide
association study, pQTL protein quantitative trait locus, SNP single-nucleotide polymorphism
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pQTL mapping. Using Bonferroni correction for multiple testing,
we identiﬁed 16,602 pQTL variants (with Reference SNP cluster
IDs) associated with 57 proteins (Supplementary Data 3),
including 11,806 cis-pQTL variants (at P < 1.25E−7, linear
regression model unless otherwise stated) for 40 proteins and
4796 trans-pQTL variants (at P < 7.04E−10) for 44 proteins; 27
proteins had both cis- and trans-pQTL variants. Our study had
80% power to detect a cis- or trans-pQTL variant that explained
≥0.6% of variance in protein levels (Supplementary Data 4). At
each pQTL locus, the SNP with the lowest P value was considered
to be the sentinel pQTL variant at that locus. Pruning of the
pQTL variants (linkage disequilibrium (LD) r2 < 0.1) yielded 372
non-redundant variants (Supplementary Data 5) representing 103
loci (Supplementary Data 6) consisting of 40 sentinel cis-pQTL
variants (Fig. 2 left panel) and 63 sentinel trans-pQTL var-
iants (Fig. 2 right panel). Among the 16,602 pQTL variants, 341
were coding variants associated with 19 proteins (Supplementary
Data 7) and 33 were rare variants (minor allele frequency < 1%
genotyped on Exome Chip) associated with 17 proteins (Sup-
plementary Data 8). In addition, 1689 insertion/deletion poly-
morphisms were identiﬁed for 55 proteins (Supplementary
Data 9).
The effect sizes and the proportion of inter-individual variation
explained by some pQTL variants were large. For example, cis-
pQTL variant rs941590, a missense SNP previously reported to be
associated with family history of venous thrombosis17, explained
32% of the inter-individual variation in SERPINA10 levels
(Supplementary Fig. 1). Three proteins (PON1, GRN, and LPA)
had pQTL variants that explained 10–30% of the variation in
circulating protein levels. Minor allele frequency was inversely
correlated with effect size (P < 0.05, Pearson correlation; Fig. 3),
and cis-pQTL variants and coding variants tended to have larger
effect sizes and explained a greater proportion of the variation in
protein levels than did trans-pQTL variants and non-coding
variants, respectively (P < 0.05, Student’s t-test; Fig. 3).
External replication. Among our 103 sentinel pQTL var-
iants linked to 57 proteins, 96 sentinel pQTL variants(36 cis- and
60 trans-pQTL variants) associated with 51 proteins were not
previously reported in GWAS. We attempted to replicate all
103 sentinel pQTL variants in the INTERVAL15 (N= 3301) and
the KORA11 studies (N= 997). Among our 57 proteins linked to
103 sentinel pQTL variants, 45 proteins (associated with 32 sen-
tinel cis-pQTL variants and 56 sentinel trans-pQTL variants)
were independently measured in the INTERVAL study. Of the
32 sentinel cis-pQTL variant-protein pairs (for 32 proteins) from
the FHS, 23 (72%) replicated in INTERVAL at P < 5.7E−4 (alpha
level of 0.05 after Bonferroni correction for 88 tests; 0.05/88). Of
the 56 sentinel trans-pQTL variant-protein pairs (for 37 proteins)
from the FHS, 33 (59%) trans-pQTL variant-protein pairs (for 22
proteins) replicated in INTERVAL (P < 5.7E−4; Supplementary
Data 10). One additional trans-pQTL variant-protein pair repli-
cated in KORA. Four proteins (associated with four cis-pQTL
variants and one trans-pQTL variant) that were not measured or
did not replicate in INTERVAL or KORA replicated based on
prior GWAS evidence (Supplementary Data 10). The remaining
10 proteins without any available external source of replication
were associated with six cis- and six trans-pQTL
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Fig. 2 Sentinel cis- and trans-pQTLs and their associated proteins. Circos plots of sentinel cis- (left panel) and trans-pQTL variants (right panel). Sentinel
pQTL variants are listed in order of chromosomal locations (blue boxes in the left semicircle). pQTL variants previously identiﬁed in GWAS to be
associated with CHD appear in red text. Proteins with genome-wide signiﬁcant pQTLs are listed in the right semicircle. The following two conditions are
summarized for each protein: (1) The corresponding protein-coding gene is a known drug target (green text). (2) GO biological processes for the protein-
coding gene (green box denotes lipid metabolism pathways, blue box denotes inﬂammatory/immune response pathways, yellow box denotes coagulation/
platelet/hemostasis pathways, and gray box denotes other pathways not included in the three most common, previously listed pathways). A single primary
GO process was chosen when the protein-coding gene was included in multiple pathways. CHD coronary heart disease, GO Gene Ontology, GWAS
genome-wide association study, pQTL protein quantitative trait locus, SNP single-nucleotide polymorphism
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Fig. 3 pQTL variant minor allele frequency vs. effect size. Minor allele
frequency of sentinel pQTL variants (X-axis) vs. effect size of variants on
proteins. The average absolute estimated effect size (per standard
deviation per allele) is signiﬁcantly different (by the unequal variance t-
test) between coding and non-coding pQTL variants (0.56 versus 0.31, P=
0.02), and also signiﬁcantly different between cis and trans-pQTL variants
(0.53 vs. 0.30, P= 0.017). pQTL protein quantitative trait locus
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variants (Supplementary Data 10). In total, 27 (75%) sentinel cis-
pQTL variants and 34 (60%) sentinel trans-pQTL var-
iants replicated (at Bonferroni-corrected P < 0.05) with 100%
consistent direction of effect compared with the FHS discovery
results.
Resampling analysis. Based on 1000 resamplings of 3300 FHS
participants in the discovery sample, 80 pQTL-protein associa-
tions (31 cis and 49 trans) yielded P < 5.7E−4 (alpha level of 0.05
after Bonferroni correction for multiple testing; 0.05/88) in ≥80%
of samplings and thus were considered likely to replicate in a
GWAS sample size of 3300 individuals from INTERVAL (Sup-
plementary Data 10). Among the 80 pQTL-protein associations
that were considered likely to replicate, 54 (68%) replicated in
INTERVAL. The discrepancy between predicted and observed
replication may be due in part to proteomic platform differences
between the discovery and replication studies.
pQTL functional and regulatory annotations. We explored the
function annotation of each protein. Some of the genes coding for
CHD-related proteins are linked to known CHD risk pathways
via previous GWAS of lipids (APOB, LPA, ANGPTL3), coagu-
lation pathways (GMP140), and systemic inﬂammation (sGP130,
sICAM1) as shown in Fig. 2. Many of the proteins that share
genetic underpinnings with CHD are known drug targets
(DrugBank database)18, or are currently under development as
such (e.g., ANGPTL3, LPA, sICAM1, and GMP140). Several
proteins with pQTLs linked to CHD, however, are not known
drug targets, particularly those from genetic loci not previously
linked to CHD risk pathways (e.g., BCHE, CXCL16, MCAM, and
sRAGE).
Colocalization of pQTLs and eQTLs. Among the 372 non-
redundant pQTL variants, we identiﬁed 190 unique variants
(associated with 53 proteins) that were also eQTL variants
(genetic variants associated with whole blood gene expression
levels in FHS participants19) at FDR < 0.05. These 190 eQTL
variants consisted of 188 cis-eQTL variants and 27 trans-eQTL
variants (Supplementary Data 11), suggesting that a substantial
number of causal eQTL variants may also be causal pQTLs. To
test this hypothesis, we conducted a Bayesian test of
colocalization of cis-pQTL variants using the coloc package in R
for genes within 1Mb region (upstream or downstream) of each
sentinel cis-pQTL variant20 (see Methods). Among the 40 sentinel
cis-pQTL variants, 26 were associated with the expression of
genes residing within 1Mb (FDR < 0.05), and these 26 unique
lead SNP-transcript-protein pairs were tested for colocalization.
Using all SNPs shared by transcripts and proteins, we conducted
a colocalization test for each protein to determine the probability
that the two association signals were due to the same causal
variant. The prior probabilities for a SNP being associated with
gene expression only (p1), protein level only (p2), or with both
traits (p12) were based on the number of eSNPs and pQTL
variants observed in our data (see Methods). The value for p12
was set to 75%, i.e., the probability that a causal eSNP is a causal
pQTL variant. For 16 out of 26 proteins that were associated with
both cis-pQTL variants and eQTL variants, we observed a
probability > 75% that the pQTL variants colocalized with the
eQTL variants (Supplementary Data 12). We observed similar
colocalization results by applying default P values (probability
values, p1= 1E−4, p2= 1E−4, p12= 1E−5) in the coloc pack-
age assuming that 1 in 10,000 SNPs is causal for either trait.
Integrating pQTL variants with CHD-associated SNPs. We
integrated our pQTL variants with 2213 CHD-related SNPs from
the CARDIoGRAMplusC4D Consortium GWAS1–3. A total of
210 pQTL variants (16 non-redundant variants at LD r2 < 0.1
representing nine proteins; Supplementary Data 13) exactly
matched SNPs associated with CHD from prior GWAS. Table 1
displays the sentinel pQTL variants that coincided with CHD-
related GWAS SNPs and the corresponding protein at each
genetic locus. The proteins with pQTL variants coinciding with
CHD-associated SNPs included LPA, APOB, B2M, CRP,
GMP140, GRN, MCAM, sGP130, and sICAM1. It is important to
note, however, that these results do not indicate a causal rela-
tionship between the pQTL-associated protein and CHD.
We found the ABO locus to have links to CHD through four
circulating proteins (GMP140, MCAM, sGP130, sICAM1). ABO
blood type has previously been linked to CVD risk in the FHS21,
and additional reports have linked the ABO locus to CVD via
coagulation pathway effects22,23. The proteins related to the ABO
locus that were identiﬁed in our study are involved in
Table 1 Proteins with pQTL variants that coincide with coronary heart disease-associated SNPs from Genome-wide Association
Studies
Measured
protein
pQTL varianta Location pQTL-annotated
gene
pQTL-protein association pQTL-CHD association
Effect
allele
EAF Beta P value Beta P valuec
APOB rs7412 19:45412079 APOE T 0.076 −0.54 9.62E−53 −0.14 8.17E−11
APOB rs12740374 1:109817590 CELSR2 T 0.215 −0.18 4.95E−16 −0.11 4.63E−23
B2M rs10774625 12:111910219 ATXN2 A 0.497 0.12 8.66E−11 0.067 2.69E−10
CRP rs12721051 19:45422160 APOC1 C 0.851 0.23 2.39E−17 −0.091 1.98E−10
GMP140 rs507666 9: 136149399 ABO A 0.818 −0.43 1.11E−72 0.080 1.64E−11
GRN rs12740374 1:109817590 CELSR2 G 0.215 0.75 2.72E−268 0.11 4.63E−23
LPA rs55730499b 6:161005610 LPA C 0.939 −1.25 3.77E−167 −0.32 4.66E−09
MCAM rs507666 9: 136149399 ABO A 0.185 −0.16 2.45E−11 0.079 1.64E−11
sGP130 rs507666 9: 136149399 ABO A 0.186 −0.21 1.68E−18 0.079 1.64E−11
sICAM1 rs507666 9: 136149399 ABO A 0.185 −0.32 4.39E−42 0.079 1.64E−11
EAF effect allele frequency, CHD coronary heart disease, pQTL protein quantitative trait locus
aFor proteins with multiple pQTL variants that coincide with coronary heart disease GWAS SNPs, the pQTL variant with the lowest P value of association with its corresponding protein level is shown
bIndicates cis-pQTL. All other pQTLs shown in this table are trans-pQTLs
cP value of associations with coronary heart disease risk in GWAS reported in the CARDIOGRAMplusC4D Consortium
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inﬂammatory pathways such as interleukin-mediated and
interferon-mediated signaling (Fig. 2). We hypothesize that the
multi-protein association of this locus may be due to the function
of the ABO-encoded protein as a glycosyltransferase.
Trans-pQTLs and CHD. Of the nine proteins with pQTL var-
iants that precisely matched CHD-associated SNPs, eight had
pQTL variants with trans effects (54 non-redundant trans-pQTL
variants in total) and 69% of these trans-pQTL variants were also
associated with the expression of nearby genes (cis-eGenes), i.e.,
these trans-pQTL variants were also cis-eQTL variants associated
with the expression of nearby cis-eGenes. Based on these ﬁndings,
we hypothesized that trans-pQTL variants may regulate circu-
lating protein levels through cis-effects on the expression of
nearby cis-eGenes (Supplementary Fig. 2a). To test this hypoth-
esis, we employed Mendelian randomization (MR)16 using the
expression of all genes within 1Mb of the trans-pQTL locus as
the exposure, cis-eQTL variants associated with these genes (from
the FHS whole-blood gene expression database19) as instrumental
variables, and circulating protein levels as the outcome. We found
that for eight proteins the effects of trans-pQTL variants on
circulating protein levels were causally regulated by the expres-
sion of cis-eGenes (Supplementary Data 14). For example, we
found decreased SH2B3 expression to be causal for higher cir-
culating B2M levels. This extends prior knowledge of the asso-
ciations of SH2B324 and B2M25 with hypertension as we
demonstrate a unidirectional causal association between SH2B3
expression and plasma B2M levels, and thus provide plausible
evidence for a causal role of the SH2B3-B2M axis in hypertension
(Supplementary Fig. 2b). To extend these ﬁndings to other CHD-
related tissues, we applied the same analyses to GTEx26 whole-
blood, liver, and heart eQTLs. For two of the proteins (APOB and
GRN), there was additional experimental evidence in support of
our results through interrogation of GTEx27 whole blood eQTLs
(Supplementary Data 14). Moreover, we found signiﬁcant causal
effects of CELSR2/SORT1/PSRC1 on APOB levels (in liver),
CELSR2/SORT1/PSRC1 on GRN levels (in artery), and ABO on
GMP140 levels (in heart atrial appendage).
Causal testing. We applied MR testing using pruned cis-pQTL
variants (LD r2 < 0.1) as instrumental variables for circulating
protein levels in order to identify proteins that were causal for
CHD. MR testing was conducted for all 40 proteins with cis-
pQTLs and causally implicated LPA, BCHE, PON1, MCAM,
MPO, and cystatin C (P < 0.05; MR test; Supplementary Data 15).
Causal testing for LPA and BCHE remained statistically sig-
niﬁcant after adjusting for multiple testing (P < 0.05/40).
Protein associations with clinical outcomes. For the 13 proteins
with pQTL variants that either coincided with CHD GWAS SNPs
(nine proteins) or tested positive by MR (six proteins) at P < 0.05,
we sought to determine the longitudinal associations of circu-
lating levels of these proteins with (a) major CHD events
(recognized myocardial infarction or CHD death; n= 213 events)
and (b) CVD death (fatal CHD or death due to stroke, peripheral
arterial disease, heart failure, or other CVD causes; n= 199
events) with a median follow-up of 14.3 years (25th percentile
11.4, 75th percentile 15.2 years) among 3520 FHS participants
50 years of age or older. Eleven of the 13 proteins were nominally
associated (P < 0.05, linear regression) with incident CHD and/or
CVD death (Table 2), and eight proteins remained statistically
signiﬁcant after adjusting for multiple testing (P < 0.05/13). Two
of the six proteins (PON1 and cystatin C) that tested causal for
CHD by MR at P < 0.05 were also associated with long-term
CHD/CVD outcomes at P < 0.0038 (Fig. 4). The protein effect
sizes on CHD predicted from MR were directionally consistent
with the observed prospective protein-CHD associations in all
cases except for PON1 (Fig. 5).
Table 2 Protein associations with coronary heart disease events and cardiovascular disease death in Framingham Heart Study
participants with long-term follow-up
Protein Association with CHD in
GWAS, MR, or both
KEGG pathways for which pQTLs
of a protein are enrichedb
Association with CHD eventsa Association with CVD deatha
Hazards ratio
(95% CI)
P valuec Hazards ratio
(95% CI)
P valuec
APOB CHD GWAS Endocytosis 1.44 (1.24–1.67) 1.8E−06 1.07 (0.91–1.26) 0.41
B2M CHD GWAS -Type I diabetes mellitus
-Antigen processing and
presentation
-Allograft rejection
-Graft vs. host disease
-Autoimmune thyroid disease
1.47 (1.24–1.75) 9.0E−06 1.97 (1.63–2.38) 2.14E−12
CRP CHD GWAS None 1.40 (1.20–1.62) 1.41E−05 1.43 (1.23–1.68) 5.78E−06
GMP140 CHD GWAS Cell adhesion molecules 1.23 (1.06–1.42) 0.0071 1.25 (1.06–1.46) 0.0063
GRN CHD GWAS None 1.14 (0.98–1.32) 0.081 1.29 (1.11–1.51) 0.0012
LPA Both None 1.09 (0.94–1.26) 0.24 1.09 (0.93–1.27) 0.29
MCAM Both None 0.88 (0.76–1.03) 0.10 1.11 (0.95–1.30) 0.19
sGP130 CHD GWAS None 1.02 (0.88–1.18) 0.80 1.34 (1.14–1.56) 0.00028
sICAM1 CHD GWAS Complement/coagulation cascades 1.23 (1.06–1.42) 0.0051 1.33 (1.14–1.55) 0.00022
PON1 MR None 0.65 (0.56–0.75) 1.83E−08 0.78 (0.66–0.92) 0.0035
BCHE MR None 1.09 (0.94–1.26) 0.25 0.82 (0.70–0.96) 0.013
MPO MR -ABC transporters
-Type II diabetes mellitus
1.16 (1.00–1.34) 0.045 1.24 (1.07–1.44) 0.0047
Cystatin C MR None 1.47 (1.24–1.73) 4.1E−06 1.77 (1.48–2.13) 5.4E−10
Hazards ratios, adjusted for age and sex, are represented per standard deviation increase in inverse-normalized protein level
CHD coronary heart disease, CI conﬁdence interval, CVD cardiovascular disease, GWAS genome-wide association study, KEGG Kyoto Encyclopedia of Genes and Genomes, MR Mendelian randomization
aCHD events (n= 213) included recognized myocardial infarction or death from CHD, and CVD death (n= 199) included fatal CHD or death due to stroke, peripheral arterial disease, heart failure, or
other CVD causes occurring during a median follow-up of 14.3 years (25th percentile 11.4, 75th percentile 15.2 years) among 3520 Framingham Heart Study participants age≥ 50 years
bFor proteins with pQTL variants that are enriched for more than ﬁve KEGG pathways, the top ﬁve most signiﬁcant pathways based on enrichment P value are shown
cThe P value threshold for signiﬁcance (P < 0.0038) was determined by the Bonferroni method (0.05/13 proteins tested). Signiﬁcant P values are shown in bold
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Proteins and pathways implicated in CHD. Six proteins were
implicated by MR analyses as nominally causal for CHD (Sup-
plementary Data 15). LPA, which interferes with the ﬁbrinolytic
cascade28, has been previously demonstrated to be causal for
CHD29, and served as a positive control. BCHE has previously
been reported to be inversely associated with long-term CVD
mortality30, and several polymorphisms within BCHE have been
reported31 to be associated with CHD risk factors. rs1803274, the
sentinel cis-pQTL variant for BCHE (A539T) (Supplementary
Data 6), is associated with decreased BCHE circulating levels and
enzymatic activity32, and has been shown to predict early-onset
CHD31. Our protein-trait analyses similarly demonstrated inverse
associations between plasma BCHE and long-term cardiovascular
outcomes, and MR analyses revealed lower BCHE to be causal for
CHD.
Four additional proteins were nominally causal for CHD by
MR. PON1 exhibits cardioprotective effects through prevention
of LDL oxidation33, and overexpression of PON1 in mice inhibits
the development of atherosclerosis34. Our protein-trait analyses
similarly demonstrated an inverse association between PON1
levels and long-term cardiovascular outcomes, but MR revealed
that higher PON1 levels are causal for CHD (Table 2). We
hypothesize that this directional discordance may reﬂect down-
regulation of PON1 expression in the setting of CHD. MPO,
which promotes formation of atherosclerotic lesions by enhan-
cing APOB oxidation within circulating LDL particles35, was
positively associated with incident cardiovascular outcomes in
our protein-trait and MR analyses. Cystatin C, a pro-
atherosclerotic36 cysteine proteinase cathepsin inhibitor and
well-characterized biomarker of CHD risk37, was also positively
associated with CVD events in our protein-trait and MR analyses.
MCAM, or CD146, was causally associated with CHD risk in an
inverse manner by MR. This is directionally consistent with prior
animal studies of limb ischemia, which have shown that injection
of sCD146 into the circulation decreased ﬁbrosis and inﬂamma-
tion and increased local perfusion38.
Several proteins lacked cis-pQTLs and therefore were unavail-
able for MR analysis. Six of these proteins had pQTL variants that
perfectly matched CHD SNPs from GWAS and were associated
with CHD/CVD outcomes in FHS participants with long-term
follow-up: GRN, sGP130, sICAM1, APOB, B2M, and CRP. GRN
has previously been implicated in atherosclerosis progression and
incident MI39. Its precursor, progranulin, has been shown to bind
to SORT1, which contains a trans-pQTL variant for GRN that is
also associated with CHD40. sGP130 levels have been shown to
positively correlate with long-term CVD mortality41, perhaps via
pathways related to hypertension and vascular remodeling42.
B2M, an essential component of the major histocompatibility
complex I43, is associated with hypertension44, atherosclerosis,
and CVD45. Finally, circulating APOB, an LDL particle ligand, is
a well-characterized biomarker of CVD risk46.
Molecular QTL browser. Our full pQTL results are available for
download through ftp://ftp.ncbi.nlm.nih.gov/eqtl/original_sub-
missions/FHS_pQTLs/ and the searchable results are accessible
through the NCBI Molecular QTL Browser (https://preview.ncbi.
nlm.nih.gov/gap/eqtl/studies/). The browser links our pQTL
results to eQTLs and other molecular resources via a user-friendly
interface. Users can browse and ﬁlter the results, for example, by
P value cutoffs. The Molecular QTL Browser also permits users to
conduct targeted studies of speciﬁc genes based on prior evidence.
MCAM
rs507666 (ABO)
rs55730499 (LPA)
rs10774625 (ATXN2 )
rs7412 (APOE)
rs12740374 (CELSR2)
rs507666 (ABO)
rs12721051 (APOC1)
pQTL variant (gene locus) that is
a CHD risk variant (P<5x10–8)
pQTL-linked
protein
LPA
MPO
BCHE
Cystatin C
Causal association
with CHD by MR
(P<0.05)
Associated with new-
onset CHD/CVD death
in framingham
(P<0.003)
CHD genome-
wide association
studies
PON1
B2M
APOB
CRP
GRN
sGP130
sICAM1
GMP140
trans-pQTL
cis-pQTL Neither
Both
Associated with new-onset CHD/CVD
Causal for CHD by MR
Fig. 4 pQTL-protein-coronary heart disease network. Network of proteins and signiﬁcant pQTL variants that are also GWAS risk SNPs for CHD. For
proteins with multiple pQTL variants that coincide with CHD GWAS SNPs, the pQTL variant with the lowest P value of association with its corresponding
protein level is shown. The following two conditions are summarized: (1) Proteins that tested causal for CHD in Mendelian randomization (P < 0.05). (2)
Proteins associated with new-onset major CHD/CVD events (P < 0.0038) in 3520 Framingham Heart Study participants 50 years of age or older with
long-term follow-up. Proteins in green fulﬁll neither condition 1 nor 2; proteins in blue fulﬁll condition 1; proteins in red fulﬁll condition 2; proteins in purple
fulﬁll conditions 1 and 2. CHD coronary heart disease, FHS Framingham Heart Study, MR Mendelian randomization, pQTL protein quantitative trait locus
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The integrated data resource enables searches across data sets and
ﬁltering by functional annotation and genomic position.
Discussion
Using a multistage strategy, we discovered over 16,000 pQTL
variants associated with 57 out of 71 proteins that were selected a
priori as high-value plasma proteins for CVD. Integration of
pQTL variants with CHD risk variants from GWAS revealed nine
proteins with pQTL variants that coincided with CHD risk var-
iants from prior GWAS (Table 1), and MR analyses implicated six
proteins as causal for CHD (Supplementary Data 15). Two of the
CHD-causal proteins were also associated with new-onset CHD
or CVD events in FHS participants with long-term follow-up
(Table 2). Thus, by integrating pQTL variants and proteins with
long-term follow-up for clinical events (Fig. 4), we demonstrated
a comprehensive approach for identifying putatively causal genes,
proteins, and pathways involved in CVD and, in doing so,
bridged a previous GWAS knowledge gap for genetic variants that
lacked known mechanistic links to disease.
We acknowledge several limitations of our study. First, parti-
cipants were of European ancestry, and therefore the results may
not be directly generalizable to populations with different ethnic/
racial backgrounds. Second, cis-pQTL coding variants alter the
amino acid sequence of the coded protein and may impact the
quantitative protein assay. Third, while our GWAS sample size
was large, our power to detect and test proteins for causality by
MR was limited. Finally, protein levels were measured in whole
blood and may not accurately reﬂect tissue-speciﬁc patterns of
expression. Furthermore, our gene transcript levels and circulat-
ing protein levels were not measured at the same point in time,
which may limit the power to colocalize protein-coding genes
with their corresponding proteins.
We have provided a large and comprehensive compilation of
pQTL variants (via the NCBI Molecular QTL Browser) and show
that an integrated genomic approach can identify proteins with
putatively causal effects on disease risk. While some of our cau-
sally implicated proteins act through classic CVD risk factors and
known pathways, others likely act through previously uni-
dentiﬁed pathways and thus represent novel targets for drug
development. Additional human and animal studies are needed to
conﬁrm our MR results and elucidate the mechanisms by which
such proteins alter CHD risk. Taken together, the pQTLs iden-
tiﬁed and analyzed in this study elucidate genes, proteins, and
pathways related to CHD, and may have profound implications
for the treatment and prevention of the leading cause of death
worldwide.
Methods
Study design. The study consisted of seven steps (Fig. 1): (1) selection and
measurement of 71 plasma proteins associated with atherosclerotic CVD via
multiplex immunoassays in 7333 FHS participants, (2) genome-wide association
study of the 71 proteins in 6861 FHS participants to identify genome-wide sig-
niﬁcant pQTL variants, (3) independent external replication of the sentinel pQTL
variants in INTERVAL, KORA and other previous GWAS, (4) functional
enrichment analyses of the identiﬁed pQTL variants, (5) integrative analyses of
Test
Mendelian randomization
Protein-trait association
Protein-trait association
Protein-trait association
Protein-trait association
Protein-trait association
0.6 0.8 1 1.2 1.4 1.6
Relative risk/hazard ratio
CHD risk 95% C.I. P value
1.20
1.09
1.09
1.02
0.65
0.82
0.88
1.08
1.04
1.47
1.16
0.96
(1.17, 1.23)
(0.94, 1.26)
(0.94, 1.26)
(0.93, 0.98)
(0.56, 0.75)
(0.76, 1.03)
(1.02, 1.14)
(1.00, 1.34)
(1.01, 1.08)
(1.25, 1.73)
(0.70, 0.95)
(1.01, 1.03)
1.74E-46
2.41E-01
2.53E-01
5.25E-03
8.57E-03
1.02E-01
1.12E-02
1.26E-02
4.06E-06
4.53E-02
1.83E-08
1.26E-03
Protein-trait association
Mendelian randomization
Mendelian randomization
Mendelian randomization
Mendelian randomization
Mendelian randomization
Protein
LPA
BCHE
PON1
MCAM
MPO
Cystatin C
Fig. 5 Protein effects on coronary heart disease from Mendelian randomization and observed protein-trait associations. A comparison of protein effects on
risk of CHD estimated from Mendelian randomization vs. the observed protein-trait associations hazards ratios. CHD coronary heart disease, CI conﬁdence
interval; CHD risk (per standard deviation increase in inverse-normalized protein level)
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pQTL variants coinciding with CHD GWAS SNPs, (6) identiﬁcation of proteins
causal for CHD using Mendelian randomization, (7) association analyses of pro-
teins from steps 5 and 6 with risk for incident CHD and CVD death in 3520 FHS
participants aged 50 years or older with available long-term follow-up.
Discovery study sample. The FHS, a community-based prospective study of CVD
and its risk factors, consists of three generations of participants within families
recruited in 1948, 1971, and 200247–49. The study samples for this investigation
were collected from 7333 participants from the FHS Offspring (Exam 7;
1998–2001) and Third Generation (Exam 1; 2002–2005) cohorts. The ﬁnal sample
for GWAS consisted of 6861 participants with complete imputed dosage data based
on the 1000 Genomes Project reference panel (1000 G build 37 phase 1 v3)50. For
association analyses using Exome Chip genotypes (see Genotyping for details), the
sample size was 6763. Genome-wide analysis of SNPs associated with gene
expression levels (eQTLs) was performed on 5257 FHS participants from Offspring
Exam 8 and Third Generation Exam 2 in whom both genotype and gene expression
data were available19.
Replication study sample. The INTERVAL bioresource is a cohort of ~50,000
whole blood donors recruited from across England between 2012 and 201415,51.
After QC, the subset of 3301 participants with imputed genetic data and protein
measurements were included in the replication analyses52. The KORA F4 study is a
prospective population-based cohort study consisting of 3080 participants living in
Augsburg, Southern Germany11,53, of which a total of 1000 participants who also
participated in a metabolomic study with follow-up information for age-related
diseases composed the replication study population. After excluding participants
with missing genotype or protein data (n= 3), the ﬁnal KORA sample included
997 individuals.
Power calculation. For power in the discovery stage with n= 6800, we assumed an
additive genetic model with no gene-gene interactions, and a population mean= 0
and standard deviation= 1 for all rank-normalized protein levels. At α= 1.25E−7
for cis-pQTL variants and 7.04E−10 for trans-pQTL variants for a two-sided test,
power was estimated for MAF= 0.002, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5
with QUANTO54. For an estimate of empirical power in the replication stage
(sample size of ~3300 in INTERVAL), we performed pQTL analyses with 1000
resamplings of 3300 FHS participants. Half of them were unrelated and the rest
were randomly sampled. We counted the number of results with P < 0.05/n in the
1000 resamplings, where n is the number of pQTL variants that were tested for
replication in INTERVAL.
Clinical measures. All FHS participants underwent periodic clinical examinations
with standard protocols49. A three-physician panel was formed to perform medical
chart review weekly. The review panel jointly assigned CVD diagnoses and causes
of death. All suspected CVD events were adjudicated by a physician panel upon
review of all available medical evidence including hospital records, personal phy-
sician records, and, in the event of out-of-hospital deaths, interviews with next of
kin. Recognized myocardial infarction (MI) was diagnosed when two of three of the
following conditions were present: prolonged chest discomfort or symptoms of
coronary ischemia, elevated biomarkers of myocardial necrosis (e.g., CK-MB or
troponin), and the development of new diagnostic Q-waves on the ECG. Fatal
CHD events included fatal MI and other deaths due to CHD as the underlying
cause in the absence of evidence of recent MI. Fatal CVD events additionally
included deaths due to stroke, peripheral arterial disease, heart failure, or other
cardiovascular causes.
Protein quantiﬁcation. FHS fasting blood plasma samples were collected and
stored at −80 °C. Candidate protein biomarkers were selected a priori based on
previous evidence of association with atherosclerotic CVD or its risk factors using
the following complementary approaches: (a) comprehensive literature search55,
(b) proteomics discovery via mass spectrometry in the FHS or elsewhere39,56, and
(c) targeting proteins coded by genes identiﬁed via gene expression proﬁling
studies57,58 or GWAS59 of atherosclerotic CVD and its risk factors (Supplementary
Data 1). A total of 85 plasma protein biomarkers were assayed using a modiﬁed
enzyme-linked immunosorbent assay sandwich method, multiplexed on a Luminex
xMAP platform (Luminex, Inc., Austin, TX). All targets were ﬁrst developed as
singleton assays before compatible targets were pooled to create multiplex panels.
Standard Luminex assays with previously published methods were used60,61.
Measurements were calibrated using a seven-point calibration curve (in triplicate)
and tested for recovery at both ends of the quantitation scale. The “High” and
“Low” spike controls (QC1 and QC2 respectively) were used to calculate intra-
assay and inter-assay coefﬁcients of variation (CV) for each protein. A total of 14
proteins had low call-rate (<90%) mainly due to values falling below the lower
detection limit that were excluded for the current study. A list of the 71 proteins
and their coefﬁcients of variation and selection criteria were shown in Supple-
mentary Data 1.
For the KORA study, plasma levels of 1129 proteins in 977 participants were
measured using the SOMAscan platform (SomaLogic Inc., Boulder, Colorado), a
multiplexed aptamer-based afﬁnity proteomics platform; 1124 proteins passed
quality control. Protein measurement protocol, normalization of protein values,
and data quality are described elsewhere12. For the INTERVAL study, plasma levels
of 3620 proteins were assayed using an extended version of the SOMAscan
platform52.
Genotyping. Genotyping and QC were conducted in the FHS17. In short, genome-
wide genotyping was conducted using the Affymetrix 500 K mapping arrays, 50 K
supplemental Human Gene Focused arrays (Affymetrix, Inc., Santa Clara, CA), and
Illumina Human Exome BeadChip v.1.0 (Exome Chip; Illumina, Inc., San Diego,
CA). Genotypes from the Affymetrix arrays were used in conjunction with the
1000 G reference panel build 37 phase 1 v350 to generate an imputed set of ~30
million variants using MACH62. SNPs with imputation quality ratio r2 < 0.5 (the
imputation quality ratio is calculated as the ratio of the variances of the observed
and estimated allele counts) were excluded, leaving a ﬁnal set of 8,509,364 SNPs for
1000 genomes-imputed GWAS.
The Exome Chip includes predominantly rare coding variants not covered by
previous genotyping arrays63. More than 90% of the SNPs included in the Exome
Chip are non-synonymous, splice, or stop codon-altering variants. Common
variants on the Exome Chip include 5542 SNPs that were selected based on their
associations with disease traits reported in the NHGRI GWAS Catalog1. Rare
variants with MAF < 1 × 10-4 were excluded from the analyses.
For INTERVAL, the Affymetrix Axiom UK Biobank Array (Affymetrix, Inc.,
Santa Clara, CA) was used to assay approximately 830,000 variants at Affymetrix
(Santa Clara, California, US), which were imputed to a combined 1000 Genomes/
UK10K reference panel. For KORA, the same array was used to genotype
3788 study participants11,53. Genotypes were then imputed from the 1000 G
reference panel14 and used to lookup the replication targets.
Functional annotation of pQTLs. We used the Functional Mapping and Anno-
tation of GWAS (FUMA; http://fuma.ctglab.nl)64 database to categorize proteins
based on known pathways and conduct functional annotation of pQTLs (regional
plot of each pQTL locus, functional categorization of pQTL SNPs, gene mapping,
and pathway enrichment analyses).
Gene expression. Gene expression proﬁling was conducted using the Affymetrix
Human Exon 1.0 ST GeneChip platform (Affymetrix Inc., Santa Clara, CA),
comprised of >5.5 million probes covering expression of 17,873 mRNA transcripts.
Gene expression values were normalized and adjusted for three technical covariates
(batch, ﬁrst principal component, and residual of probeset mean values) as
described previously19.
Coronary heart disease-associated SNPs. The CARDIoGRAMplusC4D Con-
sortium1 GWAS of CHD yielded 2213 genome-wide signiﬁcant SNPs (at P <
5E−8) from 1000 G imputation.
Genome-wide association (pQTL) analyses. Statistical analyses in the FHS were
performed using R software version 3.1.165 or SAS software version 9.4. Linear
mixed effects models (the “LMEKIN” function of Kinship Package in R) were used
to test associations of inverse-rank normalized protein levels with 1000 G or Exome
Chip variants using an additive genetic model. A cis-pQTL variant was deﬁned as a
SNP residing within 1 megabase (Mb) upstream or downstream of the transcrip-
tion start site of the corresponding protein-coding gene. A SNP located > 1Mb
upstream or downstream of the gene transcript or on a different chromosome from
its associated gene was categorized as a trans-pQTL variant. We estimated that
there were 440,409 potential cis SNP-protein pairs in total. Therefore, the
Bonferroni-corrected P value for cis-pQTL variants was calculated as 0.05/440,409
= 1.25E−7. The number of potential trans SNP-protein pairs was 8.5 million
(SNPs) × 71 (proteins)− 440,409, yielding a Bonferroni-corrected P value for
trans-pQTLs of 7.04E−10. Linkage disequilibrium (LD) was computed as the
square of Pearson’s correlation (r2) between imputed additive dosages of genotypic
variants within the same chromosome across 8481 FHS individuals with genotype
data. Independent pQTLs for a given protein were deﬁned as those with LD r2 < 0.2
with other pQTLs at a genomic locus. For a genetic locus with multiple pQTLs in
LD (i.e., LD r2 > 0.2), the pQTL with the lowest P value was selected as the sentinel
pQTL for that locus.
For KORA, linear regression models were performed on the follow-up SNPs
using R version 3.1.365. Associations between inverse-normalized protein levels and
imputed dosages were tested using linear additive genetic regression models
adjusted for age, sex, and body mass index11.
For INTERVAL, linear regression models were performed on the follow-up
SNPs using SNPTEST v2.5.2. Associations between inverse-normalized protein
levels and imputed dosages were tested using linear additive genetic regression
models adjusted for age, sex, duration between blood draw and sample processing,
and the ﬁrst three principal components of ancestry. As protein measurements
were performed in two separate batches, associations were tested within each batch,
and the results were meta-analyzed across batches using a ﬁxed-effect inverse
variance weighted meta-analysis in METAL.
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eQTL mapping. We used linear mixed-effects models, accounting for familial
relationships using “PEDIGREEMM” in R65, to assess associations between ~8.5
million additively coded 1000 G SNPs and expression levels of 17,873 transcripts19.
Models were adjusted for age, sex, platelet count, differential white cell count
(percentages of lymphocyte, monocyte, eosinophil, and basophil), and 20 PEER
factors66,67 to reduce confounding from unmeasured factors. The criteria used to
deﬁne cis and trans effects for pQTL variants were also applied to eQTL variants. A
false discovery rate (FDR) threshold of 0.05 was applied separately for cis-eQTL
and trans-eQTL variants.
Colocalization analysis. Colocalization analysis involved a two-step procedure.
Using our cis-pQTL results, we ﬁrst identiﬁed the locus that harbored the sentinel
cis-pQTL variant for each protein. The locus was deﬁned as 1 Mb region (upstream
and downstream) of each sentinel cis-pQTL variant. Using FHS eQTL results19, we
then identiﬁed all genes within each locus for which expression of a gene was
associated with the lead pQTL variant. Because eQTL analysis was based on 1000
Genomes-imputed SNPs, we used the lead pQTL variant from 1000 Genomes
imputation when the lead pQTL variant was from Exome Chip. Second, because
genes at the same locus are often correlated and regulated by the same cis SNPs, we
only retained the gene with the lowest SNP-gene association P value for each
qualifying sentinel pQTL variant, which resulted in gene-protein pairs showing
association with a common SNP and able to be tested for colocalization. To esti-
mate the probability that cis-eQTLs and cis-pQTLs residing in the same genomic
location shared the same causal variant, we conducted a Bayesian test for colo-
calization of all eQTL-pQTL pairs using the coloc package in R20. This method
requires specifying a prior probability for a SNP being associated with gene
expression only (p1), protein level only (p2), and with both traits (p12). We applied
the default P values, with p1 and p2 set to 1E−4, assuming that 1 in 10,000 SNPs
are causal for either trait and p12 was set to 1E−5. We also used p1 and p2 values
based on the number of eQTL and pQTL variants observed in our data. For the
eQTL analysis, we detected 19,613 non-redundant eSNPs among 4,285,456 total
cis-SNPs, indicating that the probability a SNP is a causal eSNP is 4.6E−3. This
probability corresponds to the sum p1+ p12. For the pQTL analysis, we detected
254 non-redundant cis-pQTL variants among 440,409 total cis-SNPs, indicating
that the probability that a SNP is a causal pQTL variant is 5.7E−4. This probability
corresponds to the sum p2+ p12. p12 was set to 0.003 corresponding to a prob-
ability of 75% that a causal eSNP is also a causal pQTL variant, an approach that
has been shown to represent the best choice68.
Mendelian randomization. Leveraging the cis-pQTL variants identiﬁed in the
current study, we used a two-sample MR approach to test for putatively causal
associations between plasma proteins and CHD risk. Summary statistics for pQTL-
CHD associations were from large meta-analyses of CARDIOGRAMplusC4D1,69.
Pruned cis-pQTL variants (LD r2 < 0.1) for each protein were used as instrumental
variables (IVs) for the corresponding protein. For proteins with only one inde-
pendent SNP after LD pruning, causal effect estimates were determined using the
Wald ratio test, i.e., a ratio of effect per risk allele on CHD to effect per risk allele
on inverse-rank normalized protein levels. When multiple non-redundant pQTL
variants were present, we conducted multi-SNP MR using inverse-variance
weighted estimates, i.e., a meta-result when using non-redundant pQTLs as an IV.
All MR analyses were conducted using MRbase70. Causal effect estimates of pro-
teins on CHD were interpreted per standard error increments in inverse-rank
normalized protein level.
Associations of protein levels with CVD. To analyze associations between
plasma protein levels and MI/CHD death and CVD death in FHS participants,
protein biomarkers were rank-normalized. Cox proportional hazard models were
used to predict MI/CHD death and CVD death for each biomarker after adjusting
for age and sex. Participants younger than 50 years of age at baseline were excluded
from outcome analyses due to a paucity of events in this age group. Participants
with prevalent MI/CHD or CVD at baseline were also excluded from the long-
itudinal analyses, leaving a ﬁnal sample size of 3520 FHS participants.
Independent external replication. After merging our 1000 G and Exome Chip
GWAS results, the pQTL variant with the lowest P value of association at each
genetic locus was selected as the sentinel pQTL variant. We conducted independent
external replication of our sentinel pQTL variants using the INTERVAL52 and
KORA studies11 and prior protein GWAS. Of the 60 proteins with pQTLs in the
FHS, replication was conducted for 48 proteins that were also measured in
INTERVAL or KORA. The sentinel pQTL variant at each genetic locus in the FHS
was determined to be successfully validated if its corresponding 1000G-imputed
genotype or strong proxy (LD r2 > 0.8) was also a signiﬁcant pQTL variant for the
corresponding protein in INTERVAL or KORA, and if directionality of pQTL-
protein association was preserved. Statistical signiﬁcance was deﬁned as a P value <
0.05/n (n was the number of pQTL variants that were measured in replication
cohorts).
Study approval. All participants from the FHS, INTERVAL, and KORA gave
informed consent for participation in this study and for the collection of plasma
and DNA for analysis. The FHS study protocol was approved by Boston Medical
Center. The INTERNAL study protocol was approved by the National Research
Ethics Service, UK (11/EE/0538). The KORA study protocol was approved by the
Ethics Committee of the Bavarian Medical Association, Germany.
Data availability. The SNP, gene expression, protein expression data that support
the ﬁndings from the FHS of this study have been deposited in dbGaP (dbGaP
Study Accession: phs000363.v16.p10). The searchable pQTL results are accessible
through the NCBI Molecular QTL Browser (https://preview.ncbi.nlm.nih.gov/gap/
eqtl/studies/). Data for INTERVAL and KORA are available upon request and are
subject to approval by the study review board.
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